JP2023537178A - ヒトnsclc細胞株及びその用途 - Google Patents
ヒトnsclc細胞株及びその用途 Download PDFInfo
- Publication number
- JP2023537178A JP2023537178A JP2022573505A JP2022573505A JP2023537178A JP 2023537178 A JP2023537178 A JP 2023537178A JP 2022573505 A JP2022573505 A JP 2022573505A JP 2022573505 A JP2022573505 A JP 2022573505A JP 2023537178 A JP2023537178 A JP 2023537178A
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- nsclc
- cell lines
- egfr
- hnsclc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 79
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 39
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000035772 mutation Effects 0.000 claims description 45
- 102200048955 rs121434569 Human genes 0.000 claims description 22
- 102200048928 rs121434568 Human genes 0.000 claims description 16
- 206010061598 Immunodeficiency Diseases 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 11
- 108700024394 Exon Proteins 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 54
- 238000010171 animal model Methods 0.000 abstract description 21
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 238000010586 diagram Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 147
- 102000001301 EGF receptor Human genes 0.000 description 50
- 108060006698 EGF receptor Proteins 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 14
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 12
- 229960003278 osimertinib Drugs 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000012827 research and development Methods 0.000 description 7
- 238000012054 celltiter-glo Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 229920003356 PDX® Polymers 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000011331 genomic analysis Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明は、ヒトNSCLC細胞株LD1-0025-200636を提供し、受託番号はCCTCC No.C202005であり、2020年6月3日に中国典型培養物保蔵センター(CCTCC)(所在地:中国、武漢、武漢大学、430072)に寄託された。
阻害率(%)=((Vコントロール群-V媒体群)-(V薬剤治療群-V媒体群))/(Vコントロール群-V媒体群)×100%
LD1-0025-200636PDXモデルは、EGFR WT NSCLC患者から確立した。LD1-0025-200694PDXモデルは、EGFRL 858R NSCLC患者から確立した。LD1-0006-215676PDXモデルは、EGFR二重変異(L858R/T790M)患者の胸水サンプルから確立した。
PDX腫瘍を採取し、HBSSに浸漬した。HBSSで腫瘍組織を洗浄して、バイオセーフティキャビネットで非腫瘍組織と壊死腫瘍組織を取り除いた。腫瘍を1~2mm3の断片に切断し、沈殿を消化バッファーで懸濁し、37℃で2~4時間インキュベートした。単一細胞を70uMフィルターで回収し、1000rpmで3分間遠心分離した。細胞を懸濁し、10mlのHistopaque溶液で遠心分離し、中層から細胞を収集した。コンディショナルリプログラミング細胞培養キットを用いて、細胞を懸濁し、培養した。安定した細胞株が得られるまで、10世代以上の細胞を連続継代させた。
CTGによって、細胞増殖をテストした。ゲノム解析は、Sangerシーケンシングによってテストした。
本研究は、ショートタンデムリピート(STR)DNA分析法を用いて、上記の新たに確立された細胞株の真正性を調査するために実施した。プロトコルは、下記のとおりである。
本開示の細胞株(即ち、LD1-0025-200636、LD1-0025-200694、LD1-0006-215676、及びLD1-0025-200717)を、96ウェルの丸底超低付着板に、2×104の細胞/ウェルで播種した。細胞株に薬を添加し、細胞を37℃及び5%CO2で6日間培養した。CellTiter-Gloを用いてATP量を測定した。薬の濃度に対応する阻害率を計算した。阻害率の計算式は下記の通りである。
本開示のNSCLC細胞株(即ち、LD1-0025-200636、LD1-0025-200694、LD1-0006-215676、及びLD1-0025-200717)に対するAZD9291のインビトロ有効性試験を実施した。結果は、図3における、AのLD1-0025-200636(EGFR WT)細胞株の阻害曲線、BのLD1-0025-200694(EGFR L858R)細胞株の阻害曲線、CのLD1-0006-215676(EGFR L858R/T790M)細胞株の阻害曲線、DのLD1-0025-200717(EGFR 19del,T790M&C797S変異体)細胞株の阻害曲線に示される。
NCGマウスは三重免疫不全であり、機能性/成熟T、B及びNK細胞を欠いており、マクロファージ及び樹状細胞の機能が低下している。これらの動物モデルは、異種移植細胞、組織及びヒト免疫系成分を定着させることができる。NCGマウスモデルの特性は、腫瘍学研究に理想的である。
Claims (13)
- 受託番号がCCTCC No.C2020103である、ヒトNSCLC細胞株LD1-0025-200717。
- T790M及びC797Sをコードするエクソン20におけるEGFR変異、並びに、エクソン19欠失746_750delを含む、請求項1に記載の細胞株。
- 受託番号がCCTCC No.C202005である、ヒトNSCLC細胞株LD1-0025-200636。
- 受託番号がCCTCC No.C2020102である、ヒトNSCLC細胞株LD1-0025-200694。
- L858Rをコードするエクソン21におけるEGFR変異を含む、請求項4に記載の細胞株。
- 受託番号がCCTCC No.C2020104である、ヒトNSCLC細胞株LD1-0006-215676。
- T790M及びL858Rをコードするエクソン20及び21におけるEGFR変異を含む、請求項6に記載の細胞株。
- 請求項1から7のいずれか一項に記載のヒトNSCLC細胞株由来の子孫細胞株。
- 請求項1から7のいずれか一項に記載のヒトNSCLC細胞株、又は請求項8に記載の子孫細胞株を含む、試薬。
- 請求項1から7のいずれか一項に記載のヒトNSCLC細胞株、請求項8に記載の子孫細胞株、又は請求項9に記載の試薬を含む、キット。
- 請求項1から7のいずれか一項に記載の細胞株、請求項8に記載の子孫細胞株、請求項9に記載の試薬、又は請求項10に記載のキットを、抗NSCLC薬の有効性を評価するために、免疫障害を有する哺乳動物にNSCLCを生成することに用いられる使用方法であって、好ましくは、前記免疫障害を有する哺乳動物は、免疫障害マウスである、使用方法。
- 請求項1から7のいずれか一項に記載のヒトNSCLC細胞株、請求項8に記載の子孫細胞株、又は請求項9に記載の試薬を、動物の体内に注入又は移植することを含み、好ましくは、前記動物は免疫障害を有する哺乳動物であり、さらに好ましくは、免疫障害を有するマウスである、動物モデルの製造方法。
- 一種又は複数種の候補薬を、請求項1から7のいずれか一項に記載のヒトNSCLC細胞株、請求項8に記載の子孫細胞株、請求項9に記載の試薬、又は請求項10に記載のキットに接触させるステップ(i)と、
細胞増殖の阻害を測定するステップ(ii)と、を含む、抗NSCLC薬の有効性を評価する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2020/094778 | 2020-06-05 | ||
CN2020094778 | 2020-06-05 | ||
PCT/CN2021/098081 WO2021244602A1 (en) | 2020-06-05 | 2021-06-03 | Human nsclc cell lines and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023537178A true JP2023537178A (ja) | 2023-08-31 |
Family
ID=78830622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022573505A Pending JP2023537178A (ja) | 2020-06-05 | 2021-06-03 | ヒトnsclc細胞株及びその用途 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4162029A1 (ja) |
JP (1) | JP2023537178A (ja) |
KR (1) | KR20230019837A (ja) |
CN (1) | CN115605584A (ja) |
AU (1) | AU2021286067A1 (ja) |
WO (1) | WO2021244602A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116355851B (zh) * | 2023-03-13 | 2023-09-08 | 广州医科大学附属第一医院(广州呼吸中心) | 一种来源于人非小细胞肺癌的原代细胞株及其制备方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015112705A2 (en) * | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
CN105777716B (zh) * | 2016-02-25 | 2018-04-10 | 清华大学 | 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
CN107311942B (zh) * | 2017-06-12 | 2019-03-26 | 哈尔滨医科大学 | 靶向肿瘤表皮生长因子受体的纳米化小分子核素探针及其制备方法与应用 |
-
2021
- 2021-06-03 WO PCT/CN2021/098081 patent/WO2021244602A1/en active Application Filing
- 2021-06-03 JP JP2022573505A patent/JP2023537178A/ja active Pending
- 2021-06-03 CN CN202180029177.2A patent/CN115605584A/zh active Pending
- 2021-06-03 AU AU2021286067A patent/AU2021286067A1/en active Pending
- 2021-06-03 KR KR1020227042063A patent/KR20230019837A/ko active Search and Examination
- 2021-06-03 EP EP21816707.0A patent/EP4162029A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230019837A (ko) | 2023-02-09 |
EP4162029A1 (en) | 2023-04-12 |
CN115605584A (zh) | 2023-01-13 |
WO2021244602A1 (en) | 2021-12-09 |
AU2021286067A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Williams et al. | Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century | |
Martin et al. | Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition | |
Bissig-Choisat et al. | Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer | |
Dong et al. | Glioma stem cells involved in tumor tissue remodeling in a xenograft model | |
WO2019006132A1 (en) | ORGANOIDS DERIVED FROM A SINGLE PULMONARY CELL | |
CN112243954B (zh) | 一种粒细胞肿瘤的pdx模型建立方法 | |
CN111793604B (zh) | 一种耐奥希替尼的人非小细胞肺癌细胞株h1975/or及其应用 | |
CN105255832B (zh) | 一种人胆管癌细胞系及其应用 | |
JP2023537178A (ja) | ヒトnsclc細胞株及びその用途 | |
CN107541494B (zh) | 一种人胆管癌细胞系及其应用 | |
JP2015167521A (ja) | 乳癌の骨髄高転移性マウス乳癌細胞株の樹立方法 | |
CN106244679A (zh) | miR‑100抑制剂在降低癌症转移中的用途 | |
CN113234679B (zh) | 一种克唑替尼耐药的人肺腺癌细胞株及其制备和应用 | |
WO2021249441A1 (zh) | 一对具有相同遗传背景和不同转移潜能的肺癌细胞株及其制备方法和用途 | |
CN113234678A (zh) | 一种对依托泊苷与卡铂联合耐药的人小细胞肺癌细胞株及其建立方法和应用 | |
CN114027256A (zh) | 高肝硬度背景sd大鼠原位肝癌模型的构建方法及其应用 | |
CN108977410B (zh) | 中国人胰腺癌原位癌细胞系 | |
CA2582236A1 (en) | Tumor models employing green fluorescent protein | |
CN113201494B (zh) | 一种黏膜黑色素瘤细胞及其用途 | |
Er | Cancer stem cells in solid tumors | |
CN109172593A (zh) | miR-516a作为治疗膀胱癌的靶标的应用 | |
Namikawa et al. | SCID-hu mice for the study of human cancer metastasis | |
CN109486767B (zh) | 一种人上皮性卵巢癌细胞shov4及其应用 | |
Ocadiz-Ruiz et al. | Human Breast Cancer Cell Lines Differentially Modulate Signaling from Distant Microenvironments, Which Reflects Their Metastatic Potential | |
CN116121192A (zh) | 对奥西替尼和厄洛替尼双耐药的人原代肺癌细胞株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221129 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20221129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230823 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240409 |